Stifel Nicolaus analyst Dylan Van Haaften maintained a Buy rating on DiaSorin S.p.A. (0GZX – Research Report) today and set a price target of €115.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Dylan Van Haaften has given his Buy rating due to a combination of factors that highlight DiaSorin S.p.A.’s strong market position and financial performance. The company reported slightly better-than-expected results for the fourth quarter, surpassing consensus estimates in both revenue and EBITDA. This solid start to the year is supported by a reiterated guidance of approximately 8% growth excluding COVID-related impacts and robust EBITDA margins of around 34%, indicating a conservative yet promising outlook.
Key growth drivers include the Immuno and LTG segments, with particularly strong performance in the U.S. market, which grew by 15%. Despite some challenges in the European market, which saw a slower growth rate, the overall revenue and strategic positioning remain strong. Additionally, the company’s ability to manage tariff impacts and foreign exchange fluctuations effectively contributes to a positive outlook, making the stock a compelling buy for investors.